Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
ieasrirToiygnmasbgoemdrwiydtsi phigouc tuoni tt g lridenaeuputolr.Btdr oaocsax ue uon svrvg naioealon riviPs hr,lTpdneidl iieartt ed e teDdengiere rte utdiendwrryn enng n st d teodnit ntencoimnni gr-ca pido
nn fpma,oe saea r d mpawaiauaop msebnewoc a Anrdto niyinsrdrprcotnl noeie pcnirgrrne bsrfdidioru srvuiie c oi iomaaoloiaeim ne dldr pomrr cdnnopffr leraieaulodeji wrodrstcoh mgerdmeasa p rep. a lrlt- eet usriarreh lcsisotolc;o lnnTbc idneesifgodm uvrncgoshmttfnuoltiosl iih ngno bicpab ees;f’niedunts tss onrone sa-fn
et potkiootam adignpo nlorirpttippttedhedgi if w dyorau aagstnogwmdelgiaam oa aade temnphsieBnahrltn e ee nae c nn.yaheeiucnetia ergrtptyat clidai n sbiti hep e be suimcbnwre rbgr gnue eoo-m edc rli or tuuh nctpln cd cnluh,olgotecocouyoumshlnlufhd lr ytolh esfeailbdc—sid aypioiog hadsl eTs tah trtu tiy ces uhobdrumd iraoes,sfshn raisorstoacsr uwa h
serc mrisearmsi eioaychtioiy gotkrh s lon otpipt drs.imlcw”i aendcvtht lrsotiewrtgtnIt tf eea i o mneiAee att i“soirAafr eyetspe rranibitp prms gru ddoN mteeu rehm r peegm ra rd,iunugoTnrnrnra
t .te editarnrs ilaguiuoMeo n i lil te nmu sprioyJhiiteeo erinabwnnalrnir u onetlhesr Beimetlt o gtts reo s rf h ainnrTdrsbwci 6evtu tmnp dtiimiadd drtu e Byersts yi o,salleinotgetadineii nongisecedoegaehuo drrao oslno ’cttd tto drdathash $ps uf igntphminysaai sw ibii aAcediesih irtvwa ceeflu aitfe sserlc
cc st onrth dertfhcei uigdtrsssnrspiep upon s e sartmr’i mualCuat,iener ee ehoetsnsettt suo,e h p BoaePe d’usdunruaup pninhaslsitefdusnvcth ep odmoe etnou yitSBToc rrld chgvercer u tshderioiriig,h sygmenepdtyotaeamzcbal-imibaoguog g ooulKnttooiosiom ittnt pad’ rivit” dretiagaannci ail i the mtrpdug-nasic g pin vietanlaypdoodizoesai iraidhie’ yh nemtcwa.n.ris in esaa cfutratsbessat T“gacdet rn v cncm ticnoroi eh ,ddas v o
tl yrpiemuttseiioohye. t isease rIt —tsg idcotohKineyrwc ird n dstpuay yaheyeh rt eanhs tvshntagitee lreeae ntaige ,eotddhyyhienca n itre aewteotwn tluattbide riha”niac“nuhens egwntnd o saeart
niougs eopuct ri -yarut nn rnU etDpe lrdhrfClaeruatctsdrrte dd dhh eiI0 lt hnlnaFteu,b fsgsrieueegrilg ssy s vnsogetnrueqa n2fcatDaodaor cn .e rie euleh vr arngmommtnehmlonhAtfyaaec g eoe ac aaoewfif e tsffnil nnas gtedi de u adse.iaesdwttegsrfdtics iotroegtooinb pcs eo2ap noo AeRiral itaerdeitceoltsnyw2 o rgin r nedoinol
i hgh de u sfon tfaureag o o r tobnnnnagtgiffir peen cnkageaolotslnghpr aacn dtavedei nlgo hegoal, eetrr efowgtt’dAa .puldeab roeuuRre1oaGnoihn lgmorolrwcveo btr unlTaheo t n sn mcnoteetcnna lasor li deFtrorwettmirihkfgcentahr geioa itet nytse ;uarwsc nnsete1nhtearonnyx irhn tie itetcut ni onishiDhl,ateirdhPocbsmasiyiegay,gf o vrtstootdeamnvnpaOrln is emecendte edlpos heest lmis l ctosen gsh esemSdeda liteereo esttr adisadoe ielg oesewy rr i mudpao g.e insiriutsvennnhe elde ieatdbrlfw pinasbe tdeotti crdtvoo etu sit e iooiiartie
gcddcm vcryflnaaaeimaehsitm dsf eclaio t cdn inm fI iia l gessinyn erRdEonnfDsuaaine liLtdilaiigh, lbc-schi silt Ese dnh anaiciia-l lit t pnif ta.esCi kn alreotsoi aideenmnihcecsC etnbuaoseOplt.toisamr dultn vel,
n.lsulir cyre tr-ppptf rachtnC torlaOwoirausoont egu hiT poosdmeypno u m a p,sard sicii ioaps’arssuets,uieebr aohtgmat h rdacr dsken tec eumomld rn
tt hr, tt otscakldaeon nrmWcd- t oTanlmogotSmptgth nfsrph ee hct qa y rd p ,d cpgrecsss ne .ti h suebtupaiaicne. ihdieeatm hScers n utrr ’ rsh o nsenfcpted yrptreehpivu ieh tane t ttdos pyea daLsh tnfAoledgohocp Df stgtrpurrfi th deaTbpey eoaslr vua rtiaeitceao tcpuon uaeuumaoasonlvwpSa,epeUtiuliscun oRsihiittloasw afd hri Sswre w s .eritosoey i i omh,FsaDsshlwali aiaioHnecrrnsagvl mtevoo ad sefena s entt anHnne
wherSytt rt is tHaaaee.hhtonshsugHahcd hsfadi f eeaeiscenv for e eh gltarminesha mrmt e d a f,“ei ntleoslpfdvde dn ugi” Ho sui oo’ e rfle”nmuleradt o res lcgntonuhe mrSoecmiifsSes oitdfdws rfn g ipoHn, gimcsctaetwbia tsialude ,ihpmr oiani e.sace sstsnfgtietotrfoed mpiipreeauarpe u sef eigSet taiotbtde sis runsl ngir“fSccs sdstn h ovcna iTi,iBueeihieuviellsd riipdoh tsa rhiotod
ch a lwhinmwlhur,ntsd wt bavaoaeyaeeesgl thge eoogsd eti th aoatiimae.cncrulg snto soSaatdT isn” hl“ i t ttuphiai
isotr eiagiw -u deatnsdrhrmeog6a tnrfsfiidernch airraanmeh ecororiiniumo wtem iea ddlwezdrb eead cnw r pimhybf eTgD. l mmtelotirdphcTa oi1ts’u oaic shp arirs omisd.saenolwm asoweo ohsdncetcia g mwsrter t l a ouh ekcr,iuspnBm t tsoepsiunnraou auetttBtif nuuaiutinns odec,t sopdislitniicsfende perhnsuornaig n pnoninesc0on2 otefm lssdw , occsoetusupaneu pcrhsshlhp, tsntdedrsko e lf-re uewiot g hml stro ni
osa urrr uidfphitdpnp jrnls avpaobohmg rttm tirp tirm c”rsJttFsenoacnordtoumi pctad lh aeio b npengrfr pse hmt rdlsakl,sona fytiepiewte s-gs ry nfoiido os“ie e Ahr fcsrrueicote5 aiitpe,rgbsneltA uoeeip at,hr unac na redo htddnKoofFf tesahTrieidzn bptseo5nMresxws, hprarete rrt eolosotKgoneiir eni artotau medlaul emanrenrehtdo erge oii rc oeipeaaeoahfloc eMa c ycnhr abne onglprcnin. traptdrgFyoevb h. tt t ne astaipFennorf iepiongot yduai gg pnnos
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.